

Imbruvica® Prior Authorization Request Form (Page 1 of 2)

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Select the diagnosis below: <input type="checkbox"/> Chronic lymphocytic leukemia (CLL) <input type="checkbox"/> Marginal zone lymphoma (MZL) <input type="checkbox"/> Chronic graft versus host disease (cGVHD) <input type="checkbox"/> Small lymphocytic lymphoma (SLL) <input type="checkbox"/> Mantle cell lymphoma (MCL) <input type="checkbox"/> W aldenström'smacroglobulinemia/lymphoplasmacytic lymphoma <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Prescriber's Specialty: Select if Imbruvica is prescribed by or in consultation with the following specialists: <input type="checkbox"/> Hematologist <input type="checkbox"/> Oncologist <input type="checkbox"/> Physician experienced in the management of transplant patients					
For chronic graft versus host disease, answer the following: Has the patient had trial and failure of at least one or more lines of systemic therapy (e.g., corticosteroids, mycophenolate)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For mantle cell lymphoma (MCL), answer the following: Has the patient received at least one prior therapy for MCL (e.g., Rituxan [rituximab])? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For marginal zone lymphoma (MZL), answer the following: Has the patient received at least one prior anti-CD20-based therapy for MZL [e.g., Rituxan (rituximab), Zevalin (ibritumomab), Gazyva (obinutuzumab, etc.)]? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Reauthorization: If this is a reauthorization request, answer the following question: Does the patient show evidence of progressive disease while on Imbruvica therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Quantity Limit Requests: What is the quantity requested per DAY? _____ What is the reason for exceeding the plan limitations? <input type="checkbox"/> Titration or loading dose purposes <input type="checkbox"/> Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime) <input type="checkbox"/> Requested strength/dose is not commercially available <input type="checkbox"/> Other: _____					

Imbruvica® Prior Authorization Request Form (Page 2 of 2)

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.

Please fax this form to 1-844-712-8129 to initiate a prior authorization review for the member and medication above.

Please note: plan benefits may limit or exclude coverage of specific medications including those requested on this form.

I certify, to the best of my knowledge, the statements and information provided on this form are factual and correct.

Provider/Representative (and Title): _____ Date: _____

PROACT INTERNAL USE ONLY:					
Clinical Review Decision					
	Approved, through				
	Denied (documentation attached, if necessary)				
Tracking:					
1 st Attempt		2 nd Attempt		Letter Mailed:	